BIOA ALERT: The Investigation on behalf of BioAge Labs - GlobeNewswire

Bleichmar Fonti & Auld LLP investigates BioAge Labs, Inc. for potential securities law violations. BioAge discontinued its Phase 2 trial for azelaprag due to safety concerns, causing a 76% stock decline. Investors may have legal options.


Related News

BIOA ALERT: The Investigation on behalf of BioAge Labs - GlobeNewswire

Bleichmar Fonti & Auld LLP investigates BioAge Labs, Inc. for potential securities law violations. BioAge discontinued its Phase 2 trial for azelaprag due to safety concerns, causing a 76% stock decline. Investors may have legal options.

© Copyright 2024. All Rights Reserved by MedPath